Secondary histiocytic sarcoma with BRAF V600E mutation responsive to MAPK‐targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR‐targeted therapy-Reference-Cited by-同舟云学术

Secondary histiocytic sarcoma with BRAF V600E mutation responsive to MAPK‐targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR‐targeted therapy

Published:2021-06 Issue:10 Volume:68 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Venkataraman Vinayak¹^ORCID,Massoth Lucas R.²,Sullivan Ryan J.³,Friedmann Alison M.⁴

Affiliation:

1. Departments of Medicine and Pediatrics Massachusetts General Hospital Boston Massachusetts USA

2. Department of Pathology Massachusetts General Hospital Boston Massachusetts USA

3. Department of Medicine Massachusetts General Hospital Boston Massachusetts USA

4. Department of Pediatrics Massachusetts General Hospital Boston Massachusetts USA

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29166

Reference20 articles.

1. Secondary histiocytic sarcoma with BRAF V600E mutation after T‐cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinib

2. Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma

3. Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment

4. Secondary histiocytic sarcoma may cause apparent persistence or recurrence of minimal residual disease in childhood acute lymphoblastic leukemia

5. Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow tranplantation for T-ALL

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. One Health: Therapies Targeting Genetic Variants in Human and Canine Histiocytic and Dendritic Cell Sarcomas;Veterinary and Comparative Oncology;2024-06-12

2. Antineoplastics;Reactions Weekly;2021-11